HPV vaccination in women 15 to 26 years of age prevents the development of cervical
intraepithelial neoplasia (CIN) 2 and CIN 3 in women regardless of previous HPV exposure …

Background: The cost-effectiveness of adding a human papillomavirus (HPV) vaccine to the
Australian National Cervical Screening Program compared to screening alone was …

Background Human papillomavirus vaccines prevent human papillomavirus infection and
cervical precancers. The impact of vaccinating women with a current infection or after …

Objectives. To examine prevalence of low-and high-grade cervical lesions over time in a
large cohort of US female adolescents and women. Methods. We used health care claims …

Importance The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9-
through 26-year-old females in 2006. Postlicensure studies in Australia, Denmark, and …

Given the low rates of Human Papillomavirus (HPV) vaccination initiation and timely series
completion in 11-and 12-year old children, we sought to assess potential opportunities for …

British Columbia launched routine immunization against human papillomavirus (HPV) in the
school year 2008–2009. Two cohorts of girls were targeted—grades 6 and 9—in order to …

The human papillomavirus (HPV) is clearly established as the cause of cervical cancer, and
vaccines targeting oncogenic forms of the virus are important as a primary method of …

Human papillomavirus (HPV) is a significant source of morbidity and mortality throughout the
world and is the most common sexually transmitted infection in the United States. HPV is the …

Background: Human papillomavirus (HPV) is a sexually transmitted infection, and HPV types
16 and 18 are responsible for approximately 66% of all US cervical cancer cases in women …